Clinical Trial Research Agreement Investigator-Initiated, Company Supported StudiesTrial Research Agreement • July 30th, 2022
The body of the Agreement is not to be amended. Revisions are to be detailed in Schedule 3 with appropriate cross-referencing to the relevant section of the Agreement.
CLINICAL TRIAL RESEARCH AGREEMENT SMLOUVA O PROVEDENÍ KLINICKÉHOTrial Research Agreement • September 5th, 2022
MERCK SHARP & DOHME s.r.o., with its address at Na Valentince 3336/4, Prague 5, Zip code 150 00, ID: 284 62 564, tax ID: CZ 284 62 564, registered in the Companies Register maintained by the Municipal Court in Prague (Section C, File No. 143294), acting in its own name at the request of Merck Sharp & Dohme LLC with its address at 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065 UA (hereinafter called “Sponsor”),
Clinical Trial Research Agreement Information (Site Details):Trial Research Agreement • August 7th, 2018
Name of Approving Authority South Eastern Sydney Local Health District Approving Authority Contact Officer Mr Tobi Wilson Position General Manager, Prince of Wales, Sydney and Sydney Eye Hospitals and Health Services Contact Phone 0293823587 Contact Email SESLHD-RSO@health.nsw.gov.au
ContractTrial Research Agreement • March 3rd, 2017
ASSIGNMENT NO. 1 POSTOUPENÍ Č. 1 This is an assignment ("Assignment") of the Clinical Trial Research Agreement entered into on 26 August 2013(the „Agreement“) by and between Toto je postoupení ("Postoupení") ke Smlouvě o provedení klinického hodnocení uzavřené 26. srpna 2013 („Smlouva“) mezi FAKULTNÍ NEMOCNICE OSTRAVA, with itsaddress at 17. listopadu 1790, zipcode: 708 52, Ostrava-Poruba, Czech Republic, company ID: 008 43 989, Tax ID: CZ00843989, Deed of foundation of the Ministry of Health of the Czech Republic from 25 November 1990 ref. No. OP-054- 25.11.90, bank details: XXX, account number: XXX IBAN: XXX, variable symbol:XXX, represented by MUDr. Josef Srovnal, the deputy director for medical care (hereinafter called "Institution"), FAKULTNÍ NEMOCNICÍ OSTRAVA, se sídlem17. listopadu 1790, PSČ: 708 52, Ostrava-Poruba, Česká republika, IČ: 008 43 989, DIČ: CZ00843989, Zřizovací listina Ministerstva zdravotnictví České republiky ze dne 25. listopadu 1990 č.j. OP-054- 25.11.90, banko
CLINICAL TRIAL RESEARCH AGREEMENT SUBCONTRACT FOR STUDIES CONDUCTED UNDER A TELE-TRIALS MODELTrial Research Agreement • April 30th, 2020
Activities means the subcontracted activities described in Item 8 of Schedule 1 both common to all Subcontractors and specific to each relevant Subcontractor as specified.
AMENDMENT 2 TO CLINICAL TRIAL RESEARCH AGREEMENTTrial Research Agreement • October 17th, 2018
(“Amendment 2”), is effective on the day of the publishing in accordance with the Act no. 340/2015 Coll. On the Register of Contracts (“Amendment 2 Effective Date”), is by and among:
CLINICAL TRIAL RESEARCH AGREEMENTTrial Research Agreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • North Carolina
This Agreement is entered into as of the last date on the signature page hereof (“Effective Date”), by and between DUKE UNIVERSITY, a nonprofit educational and health care institution located at Office of Grants and Contracts, DUMC Box 3001, 107 Seeley G. Mudd Building, Durham, NC 27710, hereinafter called “Institution,” and MEDAREX, INC., a New Jersey corporation with its principal place of business located at 707 State Road, Suite 206, Princeton, New Jersey 08540-1437, hereinafter called “Medarex”.
Clinical Trial Research AgreementTrial Research Agreement • April 20th, 2015
The body of this Agreement (that is from the following page to the execution clauses) is intended to be identical to the standard form copy available at http://www.epinet.co.nz/index.cfm?PageID=2 Any textual change to the body of this Agreement is to be ignored, and reference instead had to the standard form, as amended by Schedule 3 by way of Special Conditions.
CLINICAL TRIAL RESEARCH AGREEMENT (CTRA) REQUEST FORMTrial Research Agreement • July 22nd, 2020
Amendment to [{Clinical Trial Research Agreement}{Clinical Investigation Research Agreement}] (“Amendment”)Trial Research Agreement • May 25th, 2016
The Parties entered into a [{Clinical Trial Research Agreement}{Clinical Investigation Research Agreement}], dated [insert effective date] in relation to clinical study, [insert study title and Protocol No.] (“Agreement”)
CLINICAL TRIAL RESEARCH AGREEMENTTrial Research Agreement • May 4th, 2017
This Clinical Trial Research Agreement (“Agreement”) is made and become effective as of the day the last party to subscribe below and the Agreement will be published in the Contract Register by the statutory deadline (“Effective Date”), by and among Fakultní nemocnice Hradec Králové, located at Sokolská 581, Post Code (PSČ) 500 05, Hradec Králové –Nový Hradec Králové, Czech Republic, Company ID no.: 00179906, Tax ID no.: CZ00179906, represented by prof. MUDr. Vladimír Palička, CSc., dr. h. c., director (“Provider”) and , IV. Internal Hematology Clinic (“Principal Investigator”) and Acerta Pharma, LLC, a Delaware limited liability company, located at
ContractTrial Research Agreement • March 31st, 2017
CLINICAL TRIAL RESEARCH AGREEMENT No. 08/OVZ/16/064-P SMLOUVA O VÝZKUMNÉM KLINICKÉM HODNOCENÍ č.08/OVZ/16/064-P This Clinical Trial Research Agreement (“Agreement”) is entered into as of the date of signing by the last Party (“Effective Date”), by and among Fakultní nemocnice Ostrava, 17. listopadu 1790, 708 52 Ostrava, Czech Republic, Organization ID No.: 00843989, VAT Reg. No.: CZ00843989, person authorized to act and sign in respect of this Agreement: MUDr. Josef Srovnal, Deputy Director for Medical Care, Bank details: Česká národní banka, Na Příkopě 28, 115 03 Praha (Prague) 1, Account No.: 66332761/0710, IBAN: CZ59 0710 0000 0000 6633 2761,SWIFT: CNBACZPP, variable symbol for this study: 649071052 (“Institution”) and Prof. MUDr. Roman Hájek, CSc., with his place of work at Fakultní nemocnice Ostrava (University Hospital Ostrava), Klinika hematoonkologie (Clinic for Haematology and Oncology), 17. listopadu 1790, 708 52 Ostrava, Czech Republic (“Principal Investigator”)and Acerta Ph
Clinical Trial Research AgreementTrial Research Agreement • July 24th, 2020 • Pennsylvania
This Agreement is entered into by and between: Thomas Jefferson University, a Pennsylvania non-profit corporation whose place of business is 125 South 9th Street, Sheridan Building, Second Floor, Philadelphia, PA 19107 hereinafter called "Institution," and ____________________________a corporation with its principal office and place of business at______________________________________, hereinafter called "Sponsor."
Clinical Trial Research AgreementTrial Research Agreement • October 4th, 2020 • Pennsylvania
This Agreement is entered into by and between: Thomas Jefferson University, a Pennsylvania non-profit corporation through its Department of _______________________ with an address at Office of Research Administration, 201 S. 11th Street, Suite 303 Martin Building, Philadelphia, PA 19107 hereinafter called "Institution," and __________________________________________________ a corporation with its principal office and place of business at______________________________________, hereinafter called "Sponsor."
Clinical Trial Research Agreement New Zealand Association of Clinical Research (NZACRes) - Contract Research Organisation (CRO)Trial Research Agreement • August 27th, 2020
The body of this Agreement (that is from the following page to the execution clauses) is intended to be identical to the standard form, a copy of which is located at www.nzacres.org.nz.
AMENDMENT 2 TO CLINICAL TRIAL RESEARCH AGREEMENTTrial Research Agreement • October 18th, 2018
(“Amendment 2”), is effective on the day of the publishing in accordance with the Act no. 340/2015 Coll. On the Register of Contracts (“Amendment 2 Effective Date”), is by and among:
ContractTrial Research Agreement • November 7th, 2020 • Pennsylvania
short name of trial here) CLINICAL TRIAL RESEARCH AGREEMENT FOR THE PERFORMANCE OF AN INTERGROUP CLINICAL TRIAL BETWEEN ( Enter Name of Legal Entity represented by or acting through- Lead group/Sponsor name here, ) ANDTrial Research Agreement • February 9th, 2022
(name of legal entity here), describe type of entity here and full address, hereby represented by or acting through the (Lead GCIG Group name here ) (name of scientific structure here if applicable),
Clinical Trial Research Agreement New Zealand Association of Clinical Research (NZACRes) - Collaborative or Cooperative Research Group (CRG)Trial Research Agreement • June 26th, 2018
This Agreement is to be used where; a Collaborative or Cooperative Research Group acts as, and assumes all of the agreed responsibilities of a Sponsor, as defined by the current Committee for Proprietary Medicinal Products (CPMP)/International Conference on Harmonisation (ICH) Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95); and the approved Ethics Committee is satisfied that the Study will not be carried out principally for the benefit of the Manufacturer or distributor of the Investigational Product in question. See the Guidance Document for additional information. The body of this Agreement (that is from the following page to the execution clauses) is intended to be identical to the standard form, a copy of which is located at www.nzacres.org.nz. Any textual change to the body of this Agreement is to be ignored, and referenced instead to the standard form, as amended by Schedule 5 by way of Special Conditions. Where there is conflict between the main body of th
Clinical Trial Research Agreement Addendum New Zealand Association of Clinical Research (NZACRes) - Agreement AddendumTrial Research Agreement • September 28th, 2020
Any proposed changes to the Agreement must be incorporated by way of an addendum using this form. In providing template documents, NZACRes accepts no liability for any disputes arising from the use of its documents.
CLINICAL TRIAL RESEARCH AGREEMENT SUBCONTRACT FOR STUDIES CONDUCTED UNDER A TELE-TRIALS MODELTrial Research Agreement • May 12th, 2021
Certificate of Insurance means the certificate of insurance required pursuant to clause 15 in the manner so described in Schedule 4;
CLINICAL TRIAL RESEARCH AGREEMENTTrial Research Agreement • October 14th, 2020 • Louisiana
This Clinical Trial Research Agreement entered into this _______ day of ______________________ by and between the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, herein represented by Louisiana State University Health Sciences Center – New Orleans (hereinafter "Institution") and _______________________________ (hereinafter "Sponsor") to conduct a study entitled: __________________________________________________________
ContractTrial Research Agreement • May 16th, 2019
CLINICAL TRIAL RESEARCH AGREEMENT ZMLUVA O VÝSKUME V RÁMCI KLINICKÉHO SKÚŠANIA This Clinical Trial Research Agreement (“Agreement”) is dated as of the date last indicated on the signature page below (“Effective Date”) by and among CSL Behring GmbH having its principal place of business at CRD, Building H6, room 421, Emil-von-Behring-Str. 76, 35041, Marburg, Germany (“Sponsor”), and University Hospital Bratislava having its principal place of business address at Pažítková 4, 821 01 Bratislava, Slovak republic, Táto zmluva o výskume v rámci klinického skúšania (ďalej len „zmluva“) sa datuje od posledného dňa uvedeného na strane s podpismi nižšie (ďalej len „dátum nadobudnutia účinnosti“) a uzatvára sa medzi spoločnosťou CSL Behring GmbH, so sídlom na adrese CRD, Building H6, room 421, Emil- von-Behring-Str. 76, 35041 Marburg, Nemecko (ďalej len „zadávateľ“), a spoločnosťou Univerzitná nemocnica Bratislava, so sídlom na adrese Pažítková 4, 821 01 Bratislava, Slovenská republika, with sit
